AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33187488
Drug: Being on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Being on re‐treatment for tuberculosis
Trial: 35357078
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice daily, oral, tablets)
Trial: 32989895
Drug: Control (Adper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Adper Single Bond 2 without additional treatment)
Trial: 34535330
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of remifentanil starting at 0.1 mcg/kg/min, increased to 1 mcg/kg/min if required
Trial: 34535330
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus patient-controlled sedation analgesia (PCSA) with remifentanil infusion at 0.05 mcg/kg per minute and bolus of 0.1 mcg/kg with lock-out time of 3 minutes
Trial: 34753154
Drug: Unbuffered lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unbuffered lidocaine needle‐free injection
Trial: 32376628
Drug: ELX-02 (0.3-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELX-02 (0.3-7.5 mg/kg)
Trial: 32376628
Drug: ELX-02 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELX-02 (20 and 100 μg/ml)
Trial: 33501904
Drug: 360 mL
RxNorm normalized name: colostomy bags 10" 360 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mL of water
Trial: 34923285
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg plus methotrexate (MTX)
Trial: 33155295
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training with supplemental oxygen (10 L/min)
Trial: 33155295
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training with medical air (10 L/min)
Trial: 36219061
Drug: Crisaborole 2%
RxNorm normalized name: CRISABOROLE 2% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole 2% ointment with weekly email surveys for 6 weeks, then monthly for 12 months (intervention group)
Trial: 36219061
Drug: Crisaborole 2%
RxNorm normalized name: CRISABOROLE 2% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole 2% ointment without email surveys (control group)
Trial: 33142117
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of compensatory neuronal innervation using LOXO-101, a Trk-NGF inhibitor.
Trial: 32704168
Drug: Non-automated ML
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-automated ML approach
Trial: 34101496
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) of 61.6 Gy to the primary tumor
Trial: 34101496
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of 50.4 Gy to the tumor and regional lymph nodes
Trial: 32331010
Drug: OLZ/SAM 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ/SAM 10/10 mg, 20/20 mg, 30/30 mg
Trial: 34808678
Drug: Intra-Arterial Nimodipine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-Arterial Nimodipine Infusion (IANI)
Trial: 35710164
Drug: Fruit-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit-rich diet (FRD) with at least 4 servings of fruits daily
Trial: 34170090
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody against IBV M41 S1 protein
Trial: 33121832
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine applied every 30 minutes as needed for 24 hours
Trial: 34942092
Drug: Second intravenous
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second intravenous immunoglobulin
Trial: 32819191
Drug: Caffeine-nap (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-nap (200 mg caffeine prior to a 30 min nap)
Trial: 36380299
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) plus usual care (UC)
Trial: 33088309
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Trial: 33088309
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Trial: 33088309
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Trial: 33088309
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Vaginal, Sublingual, Oral)
Trial: 33753329
Drug: TAF/FTC 25/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21; GSK3640254 200 mg QD added on days 15 through 21
Trial: 33753329
Drug: TAF/FTC 25/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21
Trial: 33753329
Drug: GSK3640254 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 200 mg QD
Trial: 32700995
Drug: NaI (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaI (20 mg/kg, PO, 2 doses 72 hours apart; n = 211)
Trial: 35670064
Drug: Individualized reverse‐calculation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized reverse‐calculation doses
Trial: 33472996
Drug: Endostar combined
RxNorm normalized name: Menostar
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endostar combined with chemotherapy (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Trial: 33587443
Drug: Colchicine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.6 mg daily)
Trial: 36441433
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg/day for 16 weeks
Trial: 32736540
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype)
Trial: 32736540
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus chemotherapy
Trial: 35437881
Drug: Topical oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxygen therapy and standard of care (TOT/SOC)
Trial: 36103844
Drug: Su Jok
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Su Jok seed therapy
Trial: 36738762
Drug: Golimumab monotherapy
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab monotherapy
Trial: 33234578
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment strategy using monoclonal antibodies combined with optimally sequenced chemotherapy
Trial: 34146120
Drug: TRE cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRE cream (0.05% tretinoin cream)
Trial: 35859328
Drug: PEG-rhG-CSF as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF as primary prophylactic therapy
Trial: 35859328
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rhG-CSF administered when white blood cell count was <2.0 × 10^9/L or absolute neutrophil count <1.0 × 10^9/L)
Trial: 38190136
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy only)
Trial: 32189364
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy after lamivudine resistance
Trial: 33946085
Drug: Fostemsavir 600
RxNorm normalized name: fostemsavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 600 mg twice daily with optimized background therapy (OBT)
Trial: 32750261
Drug: DTaP-IPV-Hib-HepB vaccine
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-Hib-HepB vaccine
Trial: 32750261
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (PENTACEL™ or INFANRIX™ hexa)
Trial: 36029653
Drug: FP/bevacizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/bevacizumab + atezolizumab (800 mg 60-min i.v. infusion q2 weeks)
Trial: 32861217
Drug: Esketamine 84
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 84 mg nasal spray twice weekly for 4 weeks with standard of care
Trial: 32861217
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray twice weekly for 4 weeks with standard of care
Trial: 33856570
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous teriparatide (TPD) 20 mcg
Trial: 33856570
Drug: Cyclic teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cyclic teriparatide (TPD) followed by raloxifene (RLX) 60 mg
Trial: 35278336
Drug: Control (implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (implant surgery alone)
Trial: 34072293
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (2.3 g omega-3 daily)
Trial: 33118519
Drug: Urea ointment
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea ointment
Trial: 35243421
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied lactobacilli, daily application for 8 weeks.
Trial: 36176927
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chinese herbal fumigation sitz-bath and red ointment
Trial: 36176927
Drug: Red ointment
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ointment therapy
Trial: 34170932
Drug: FPG ADA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG ADA definition (5.6-6.9 mmol/l)
Trial: 32481390
Drug: Extralevator abdominoperineal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extralevator abdominoperineal resection (L-ELAPE)
Trial: 34228836
Drug: Dipyrone 30
RxNorm normalized name: dipyrone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 30 mg/kg q12h
Trial: 34228836
Drug: Dipyrone 30
RxNorm normalized name: dipyrone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 30 mg/kg q8h
Trial: 34228836
Drug: Dipyrone 60
RxNorm normalized name: dipyrone 606 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 60 mg/kg q8h
Trial: 34228836
Drug: Dipyrone 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 90 mg/kg q12h
Trial: 32075695
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (TMI) adjunct to standard care (30-min group-based smoking cessation counseling and nicotine patches)
Trial: 32075695
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (30-min group-based smoking cessation counseling and nicotine patches)
Trial: 32014846
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise and health coaching intervention including 1 weekly supervised exercise session.
Trial: 37522226
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments combined
Trial: 35022952
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (500 mg)
Trial: 36047381
Drug: Empowering Community
RxNorm normalized name: Empowered Choice
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Empowering Community Pharmacists program (monthly resources/reminders + educational webinar)
Trial: 36047381
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly reminders only)
Trial: 33413291
Drug: IND/GLY/MF 150/50/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF 150/50/80 μg (ICS medium-dose)
Trial: 33413291
Drug: IND/GLY/MF 150/50/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF 150/50/160 μg (ICS high-dose)
Trial: 33413291
Drug: IND/GLY/MF (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF (both doses)
Trial: 32106885
Drug: Intervention package
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention package consisting of structured sessions of behavior activation, problem-solving treatment, and parenting skills training delivered by primary maternal health care providers and supported by a 'neighborhood mother'.
Trial: 32933470
Drug: Ultrasound-guided great
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided great auricular nerve block (GANB) with 2 ml of 0.25% ropivacaine
Trial: 34385093
Drug: Processed Aloe
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Processed Aloe Vera Gel (PAG)
Trial: 32804414
Drug: Synthesized dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthesized dynamic treatment regimes (DTRs)
Trial: 36001752
Drug: CNI (Calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI (Calcineurin Inhibitors)
Trial: 32077231
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg ZGN-1061
Trial: 32077231
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg ZGN-1061
Trial: 35596803
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg/day
Trial: 33634687
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction (MPFF) standard dose of 1000 mg once daily for 2 months (group 1)
Trial: 33634687
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction (MPFF) double dose of 1000 mg twice daily for 1 month and then 1000 mg once daily for 1 month (group 2)
Trial: 33735635
Drug: Omeprazole capsule
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole capsule
Trial: 32178701
Drug: Astragalus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus injection
Trial: 32178701
Drug: Salvia Miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia Miltiorrhiza injection
Trial: 32178701
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including treatment and control)
Trial: 34830950
Drug: Ultra-hypofractionated RT/stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-hypofractionated RT/stereotactic body RT with focal RT dose escalation on intraprostatic tumor sides
Trial: 36289039
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard radiation therapy workflow)
Trial: 33527809
Drug: Azilsartan 40
RxNorm normalized name: azilsartan 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 40 mg
Trial: 33527809
Drug: Azilsartan 80
RxNorm normalized name: azilsartan 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 80 mg
Trial: 35932889
Drug: Immediate telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate telephone smoking cessation intervention (TSI) support with appropriate pharmacotherapy for 6 weeks
Trial: 33521132
Drug: L-carnitine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine therapy
Trial: 32830463
Drug: Oral Janus
RxNorm normalized name: Ricinus nanus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Janus kinase 1 (JAK1) inhibitor abrocitinib (dose range 10-200 mg)
Trial: 36242741
Drug: Vidofludimus calcium
RxNorm normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidofludimus calcium (45 mg for 14 days)
Trial: 33823960
Drug: Food-related behavioral
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-related behavioral activation (F-BA) therapy with placebo supplements
Trial: 33823960
Drug: Multi-nutrient supplements
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient supplements (omega-3 fatty acids and a multi-vitamin)
Trial: 33823960
Drug: F-BA therapy
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-BA therapy with multi-nutrient supplements
Trial: 35760971
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion of piperacillin/tazobactam
Trial: 35760971
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin/tazobactam
Trial: 34398235
Drug: Varenicline vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline vs Nicotine patches
Trial: 33060783
Drug: Duodenal acid
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal acid infusion
Trial: 33997052
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment prior to restoration
Trial: 33044435
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise (150 min·wk‐1)
Trial: 33044435
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise (300 min·wk‐1)
Trial: 36942507
Drug: Placebo (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multiple dose)
Trial: 35299272
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicines (IHM) in centesimal potencies
Trial: 34182967
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with a diode laser (810 nm wavelength, 100 mW power output, 6.29 J/cm2 energy density) applied on days 0, 7, 14, and 21 after loading the canine retraction forces.
Trial: 34677118
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pharmacological treatment only)
Trial: 33932574
Drug: PHARM-DC intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PHARM-DC intervention (pharmacist-directed transitional care including medication reconciliation, medication review, increased communication, patient education and counseling)
Trial: 34218277
Drug: Particle Beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particle Beam Therapy (PBT)
Trial: 33111932
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at rates of 0, 4.0, 8.0, and 16 g L‐1 under three soil water conditions (50% and 100% of soil water retention capacity and complete submergence in a water blade of 5.0 cm)
Trial: 32241356
Drug: Custom cantilever
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Custom cantilever appliance producing 100 g of force for buccal translation
Trial: 34855690
Drug: Stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulants
Trial: 35475308
Drug: 75 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg/kg eptacog beta initial dose regimen (IDR)
Trial: 35475308
Drug: 225 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 μg/kg eptacog beta initial dose regimen (IDR)
Trial: 32151752
Drug: Brief advice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief advice (BA) to exercise alone (minimal treatment control condition)